share_log

Esperion Therapeutics Analyst Ratings

Esperion Therapeutics Analyst Ratings

Esperion Therapeutics 分析
Benzinga ·  2023/10/02 06:29
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
10/02/2023 791.09% Needham → $9 Reiterates Buy → Buy
08/28/2023 2078.22% HC Wainwright & Co. → $22 Reiterates Buy → Buy
08/02/2023 791.09% Needham $10 → $9 Maintains Buy
06/26/2023 2078.22% HC Wainwright & Co. → $22 Reiterates Buy → Buy
06/15/2023 296.04% B of A Securities $1.25 → $4 Upgrades Underperform → Buy
06/01/2023 2078.22% HC Wainwright & Co. → $22 Reiterates → Buy
05/09/2023 890.1% Needham $12 → $10 Maintains Buy
04/18/2023 1088.12% Needham → $12 Reiterates → Buy
03/28/2023 1088.12% Needham → $12 Reiterates → Buy
03/20/2023 197.03% Morgan Stanley $9 → $3 Maintains Equal-Weight
03/16/2023 48.51% B of A Securities $8 → $1.5 Downgrades Neutral → Underperform
03/16/2023 1088.12% Needham $16 → $12 Maintains Buy
03/16/2023 2078.22% HC Wainwright & Co. → $22 Reiterates → Buy
03/07/2023 593.07% Credit Suisse $6.5 → $7 Upgrades Underperform → Neutral
03/06/2023 1385.15% JMP Securities → $15 Reiterates → Market Outperform
03/06/2023 1484.16% Needham $12 → $16 Maintains Buy
03/06/2023 2078.22% HC Wainwright & Co. → $22 Reiterates → Buy
02/27/2023 791.09% JP Morgan $8 → $9 Maintains Neutral
02/27/2023 692.08% B of A Securities → $8 Reinstates → Neutral
02/22/2023 1088.12% Needham → $12 Reiterates → Buy
02/03/2023 791.09% Morgan Stanley → $9 Upgrades Underweight → Equal-Weight
11/02/2022 791.09% Morgan Stanley $7 → $9 Maintains Underweight
08/03/2022 494.06% Credit Suisse $7 → $6 Downgrades Neutral → Underperform
07/15/2022 593.07% Morgan Stanley $5 → $7 Maintains Underweight
05/24/2022 197.03% Goldman Sachs $3.5 → $3 Maintains Sell
05/05/2022 — JP Morgan Upgrades Underweight → Neutral
03/10/2022 2078.22% HC Wainwright & Co. → $22 Initiates Coverage On → Buy
01/14/2022 494.06% Credit Suisse $8 → $6 Maintains Neutral
12/09/2021 1088.12% Needham $20 → $12 Maintains Buy
12/06/2021 395.05% Goldman Sachs $8 → $5 Maintains Sell
12/06/2021 692.08% Credit Suisse $11 → $8 Maintains Neutral
10/19/2021 989.11% Credit Suisse $28 → $11 Downgrades Outperform → Neutral
10/14/2021 989.11% Morgan Stanley → $11 Downgrades Equal-Weight → Underweight
08/04/2021 1583.17% Morgan Stanley $22 → $17 Maintains Equal-Weight
08/03/2021 11187.13% Needham $134 → $114 Maintains Strong Buy
05/05/2021 3464.36% Credit Suisse $45 → $36 Maintains Outperform
05/05/2021 2276.24% Northland Capital Markets $30 → $24 Maintains Market Perform
05/05/2021 2078.22% Morgan Stanley $30 → $22 Maintains Equal-Weight
05/05/2021 10890.1% JMP Securities $191 → $111 Maintains Market Outperform
05/05/2021 1880.2% Stifel $37 → $20 Downgrades Buy → Hold
03/11/2021 2870.3% Morgan Stanley → $30 Initiates Coverage On → Equal-Weight
02/24/2021 13167.33% Needham $150 → $134 Maintains Strong Buy
02/12/2021 2870.3% Jefferies $40 → $30 Downgrades Buy → Hold
02/09/2021 2276.24% Goldman Sachs → $24 Downgrades Neutral → Sell
01/15/2021 3365.35% B of A Securities → $35 Downgrades Buy → Neutral
11/10/2020 — Credit Suisse Upgrades Neutral → Outperform
10/15/2020 5048.51% B of A Securities $55 → $52 Maintains Buy
08/17/2020 5345.54% B of A Securities $60 → $55 Maintains Buy
08/11/2020 4355.45% Credit Suisse $83 → $45 Downgrades Outperform → Neutral
05/07/2020 6830.69% Jefferies $85 → $70 Maintains Buy
04/16/2020 4058.42% Northland Capital Markets $60 → $42 Maintains Market Perform
04/01/2020 4850.5% B of A Securities → $50 Initiates Coverage On → Buy
03/17/2020 — Citigroup Upgrades Neutral → Buy
02/28/2020 4553.47% JP Morgan $46 → $47 Maintains Neutral
02/24/2020 15543.56% Needham $144 → $158 Maintains Strong Buy
02/24/2020 — Northland Capital Markets Downgrades Outperform → Market Perform
02/14/2020 8018.81% Citigroup $73 → $82 Downgrades Buy → Neutral
09/18/2019 6830.69% Stifel $112 → $70 Maintains Buy
09/16/2019 4355.45% Goldman Sachs $55 → $45 Upgrades Sell → Neutral
05/29/2019 4850.5% Goldman Sachs → $50 Downgrades Neutral → Sell
04/26/2019 — Goldman Sachs Upgrades Sell → Neutral
03/13/2019 4553.47% JP Morgan $38 → $47 Upgrades Underweight → Neutral
12/13/2018 4355.45% Goldman Sachs → $45 Initiates Coverage On → Sell
10/16/2018 8018.81% BTIG → $82 Initiates Coverage On → Buy
日期 上行/下行 分析公司 目標價格變化 評級變化 上一次/當前評級
10/02/2023 791.09% 李約瑟 →$9 重申 購買→購買
2023年08月28日 2078.22% HC Wainwright公司 →$22 重申 購買→購買
08/02/2023 791.09% 李約瑟 $10→$9 維護 買
2023/06/26 2078.22% HC Wainwright公司 →$22 重申 購買→購買
2023/06/15 296.04% B of A證券 $1.25→$4 升級 表現不佳的→收購
06/01/2023 2078.22% HC Wainwright公司 →$22 重申 →購買
05/09/2023 890.1% 李約瑟 $12→$10 維護 買
04/18/2023 1088.12% 李約瑟 →$12 重申 →購買
03/28/2023 1088.12% 李約瑟 →$12 重申 →購買
03/20/2023 197.03% 摩根士丹利 $9→$3 維護 等重
03/16/2023 48.51% B of A證券 $8→$1.5 評級下調 中性→表現不佳
03/16/2023 1088.12% 李約瑟 $16→$12 維護 買
03/16/2023 2078.22% HC Wainwright公司 →$22 重申 →購買
03/07/2023 593.07% 瑞士信貸 $6.5→$7 升級 表現不佳的→中性
03/06/2023 1385.15% JMP證券 →$15 重申 →市場跑贏大盤
03/06/2023 1484.16% 李約瑟 $12→$16 維護 買
03/06/2023 2078.22% HC Wainwright公司 →$22 重申 →購買
02/27/2023 791.09% 摩根大通 $8→$9 維護 中性
02/27/2023 692.08% B of A證券 →$8 恢復 →中性
02/22/2023 1088.12% 李約瑟 →$12 重申 →購買
02/03/2023 791.09% 摩根士丹利 →$9 升級 重量不足的→等重
11/02/2022 791.09% 摩根士丹利 $7→$9 維護 體重不足
08/03/2022 494.06% 瑞士信貸 $7→$6 評級下調 中性→表現不佳
07/15/2022 593.07% 摩根士丹利 $5→$7 維護 體重不足
2022年05月24日 197.03% 高盛 $3.5→$3 維護 賣
05/05/2022 - 摩根大通 升級 減重→中性
03/10/2022 2078.22% HC Wainwright公司 →$22 開始承保 →購買
2022年01月14日 494.06% 瑞士信貸 $8→$6 維護 中性
12/09/2021 1088.12% 李約瑟 $20→$12 維護 買
12/06/2021 395.05% 高盛 $8→$5 維護 賣
12/06/2021 692.08% 瑞士信貸 $11→$8 維護 中性
10/19/2021 989.11% 瑞士信貸 $28→$11 評級下調 跑贏→中性
10/14/2021 989.11% 摩根士丹利 →$11 評級下調 等重→減碼
08/04/2021 1583.17% 摩根士丹利 $22→$17 維護 等重
08/03/2021 11187.13% 李約瑟 $134→$114 維護 強勢購買
05/05/2021 3464.36% 瑞士信貸 $45→$36 維護 跑贏大盤
05/05/2021 2276.24% 北國資本市場 $30→$24 維護 市場表現
05/05/2021 2078.22% 摩根士丹利 $30→$22 維護 等重
05/05/2021 10890.1% JMP證券 $191→$111 維護 市場表現強於大盤
05/05/2021 1880.2% Stifel $37→$20 評級下調 購買→Hold
03/11/2021 2870.3% 摩根士丹利 →$30 開始承保 →等重
02/24/2021 13167.33% 李約瑟 $150→$134 維護 強勢購買
02/12/2021 2870.3% 傑富瑞 $40→$30 評級下調 購買→Hold
02/09/2021 2276.24% 高盛 →$24 評級下調 中性→銷售
2021/01/15 3365.35% B of A證券 →$35 評級下調 購買→中性
11/10/2020 - 瑞士信貸 升級 中性→表現優異
10/15/2020 5048.51% B of A證券 $55→$52 維護 買
2020/08/17 5345.54% B of A證券 $60→$55 維護 買
2020年08月11日 4355.45% 瑞士信貸 $83→$45 評級下調 跑贏→中性
05/07/2020 6830.69% 傑富瑞 $85→$70 維護 買
04/16/2020 4058.42% 北國資本市場 $60→$42 維護 市場表現
04/01/2020 4850.5% B of A證券 →$50 開始承保 →購買
03/17/2020 - 花旗集團 升級 中性→購買
02/28/2020 4553.47% 摩根大通 $46→$47 維護 中性
02/24/2020 15543.56% 李約瑟 $144→$158 維護 強勢購買
02/24/2020 - 北國資本市場 評級下調 跑贏→市場表現
02/14/2020 8018.81% 花旗集團 $73→$82 評級下調 購買→中性
2019年09月18日 6830.69% Stifel $112→$70 維護 買
2019/09/16 4355.45% 高盛 $55→$45 升級 賣出→中性
2019年05月29日 4850.5% 高盛 →$50 評級下調 中性→銷售
2019年04月26日 - 高盛 升級 賣出→中性
2019/03/13 4553.47% 摩根大通 $38→$47 升級 減重→中性
2018年12月13日 4355.45% 高盛 →$45 開始承保 →銷售
2018年10月16日 8018.81% BTIG →$82 開始承保 →購買

What is the target price for Esperion Therapeutics (ESPR)?

Esperion Treateutics(ESPR)的目標價格是多少？

The latest price target for Esperion Therapeutics (NASDAQ: ESPR) was reported by Needham on October 2, 2023. The analyst firm set a price target for $9.00 expecting ESPR to rise to within 12 months (a possible 791.09% upside). 22 analyst firms have reported ratings in the last year.

Needham於2023年10月2日報道了Esperion治療公司(納斯達克：ESPR)的最新目標價。這家分析公司將目標價定為9美元，預計每股收益將在12個月內升至(可能上漲791.09%)。過去一年，有22家分析公司公佈了評級。

What is the most recent analyst rating for Esperion Therapeutics (ESPR)?

Esperion Treateutics(ESPR)的最新分析師評級是什麼？

The latest analyst rating for Esperion Therapeutics (NASDAQ: ESPR) was provided by Needham, and Esperion Therapeutics reiterated their buy rating.

Needham提供了對Esperion Treateutics(納斯達克代碼：ESPR)的最新分析師評級，Esperion Treateutics重申了他們的買入評級。

When is the next analyst rating going to be posted or updated for Esperion Therapeutics (ESPR)?

Esperion Treeutics(ESPR)的下一次分析師評級將於何時發佈或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Esperion Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Esperion Therapeutics was filed on October 2, 2023 so you should expect the next rating to be made available sometime around October 2, 2024.

分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與Esperion Treeutics的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Esperion治療公司的上一次評級是在2023年10月2日提交的，所以你應該預計下一次評級將在2024年10月2日左右的某個時候提供。

Is the Analyst Rating Esperion Therapeutics (ESPR) correct?

分析師對Esperion Treeutics(ESPR)的評級正確嗎？

While ratings are subjective and will change, the latest Esperion Therapeutics (ESPR) rating was a reiterated with a price target of $0.00 to $9.00. The current price Esperion Therapeutics (ESPR) is trading at is $1.01, which is within the analyst's predicted range.

雖然評級是主觀的，並將發生變化，但最新的Esperion治療(ESPR)評級被重申，目標價在0.00美元至9.00美元之間。Esperion Treateutics(ESPR)目前的交易價格為1.01美元，在分析師的預測範圍內。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間